Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103

1.

Measurement of human and mouse interleukin-12.

Gately MK, Chizzonite R, Presky DH.

Curr Protoc Immunol. 2001 May;Chapter 6:Unit 6.16. doi: 10.1002/0471142735.im0616s15.

PMID:
18432807
2.

In vitro and in vivo responses to interleukin 12 are maintained until the late SIV infection stage but lost during AIDS.

Villinger F, Bucur S, Chikkala NF, Brar SS, Bostik P, Mayne AE, Adams J, Lee ME, Novembre FJ, Gately MK, Ansari AA, Hillyer CD.

AIDS Res Hum Retroviruses. 2000 May 20;16(8):751-63.

PMID:
10826482
3.

Down-regulation of the pharmacokinetic-pharmacodynamic response to interleukin-12 during long-term administration to patients with renal cell carcinoma and evaluation of the mechanism of this "adaptive response" in mice.

Rakhit A, Yeon MM, Ferrante J, Fettner S, Nadeau R, Motzer R, Bukowski R, Carvajal DM, Wilkinson VL, Presky DH, Magram J, Gately MK.

Clin Pharmacol Ther. 1999 Jun;65(6):615-29.

PMID:
10391667
4.

IL-12 is dispensable for innate and adaptive immunity against low doses of Listeria monocytogenes.

Brombacher F, Dorfmüller A, Magram J, Dai WJ, Köhler G, Wunderlin A, Palmer-Lehmann K, Gately MK, Alber G.

Int Immunol. 1999 Mar;11(3):325-32.

PMID:
10221644
5.

Interleukin-12 is essential for a protective Th1 response in mice infected with Cryptococcus neoformans.

Decken K, Köhler G, Palmer-Lehmann K, Wunderlin A, Mattner F, Magram J, Gately MK, Alber G.

Infect Immun. 1998 Oct;66(10):4994-5000.

6.

The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses.

Gately MK, Renzetti LM, Magram J, Stern AS, Adorini L, Gubler U, Presky DH.

Annu Rev Immunol. 1998;16:495-521. Review.

PMID:
9597139
7.

Analysis of the multiple interactions between IL-12 and the high affinity IL-12 receptor complex.

Presky DH, Minetti LJ, Gillessen S, Wilkinson VL, Wu CY, Gubler U, Chizzonite R, Gately MK.

J Immunol. 1998 Mar 1;160(5):2174-9.

8.

Treatment with homodimeric interleukin-12 (IL-12) p40 protects mice from IL-12-dependent shock but not from tumor necrosis factor alpha-dependent shock.

Mattner F, Ozmen L, Podlaski FJ, Wilkinson VL, Presky DH, Gately MK, Alber G.

Infect Immun. 1997 Nov;65(11):4734-7.

9.

Deviation of pancreas-infiltrating cells to Th2 by interleukin-12 antagonist administration inhibits autoimmune diabetes.

Trembleau S, Penna G, Gregori S, Gately MK, Adorini L.

Eur J Immunol. 1997 Sep;27(9):2330-9.

PMID:
9341777
11.

Targeting IL-12, the key cytokine driving Th1-mediated autoimmune diseases.

Adorini L, Aloisi F, Galbiati F, Gately MK, Gregori S, Penna G, Ria F, Smiroldo S, Trembleau S.

Chem Immunol. 1997;68:175-97. Review. No abstract available.

PMID:
9329222
12.
13.

Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo.

Lieschke GJ, Rao PK, Gately MK, Mulligan RC.

Nat Biotechnol. 1997 Jan;15(1):35-40.

PMID:
9035103
14.

Regulation of interleukin-12 receptor beta1 chain expression and interleukin-12 binding by human peripheral blood mononuclear cells.

Wu C, Warrier RR, Wang X, Presky DH, Gately MK.

Eur J Immunol. 1997 Jan;27(1):147-54.

PMID:
9022011
15.

Sterile protection of monkeys against malaria after administration of interleukin-12.

Hoffman SL, Crutcher JM, Puri SK, Ansari AA, Villinger F, Franke ED, Singh PP, Finkelman F, Gately MK, Dutta GP, Sedegah M.

Nat Med. 1997 Jan;3(1):80-3.

PMID:
8986746
16.

Reduced incidence and severity of collagen-induced arthritis in interleukin-12-deficient mice.

McIntyre KW, Shuster DJ, Gillooly KM, Warrier RR, Connaughton SE, Hall LB, Arp LH, Gately MK, Magram J.

Eur J Immunol. 1996 Dec;26(12):2933-8.

PMID:
8977288
17.

A functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunits.

Presky DH, Yang H, Minetti LJ, Chua AO, Nabavi N, Wu CY, Gately MK, Gubler U.

Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):14002-7.

18.

Evidence for multiple sites of interaction between IL-12 and its receptor.

Presky DH, Minetti LJ, Gillessen S, Gubler U, Chizzonite R, Stern AS, Gately MK.

Ann N Y Acad Sci. 1996 Oct 31;795:390-3.

PMID:
8958964
19.

IL-12-deficient mice are defective but not devoid of type 1 cytokine responses.

Magram J, Sfarra J, Connaughton S, Faherty D, Warrier R, Carvajal D, Wu CY, Stewart C, Sarmiento U, Gately MK.

Ann N Y Acad Sci. 1996 Oct 31;795:60-70.

PMID:
8958917
20.

Interleukin-12 antagonist activity of mouse interleukin-12 p40 homodimer in vitro and in vivo.

Gately MK, Carvajal DM, Connaughton SE, Gillessen S, Warrier RR, Kolinsky KD, Wilkinson VL, Dwyer CM, Higgins GF Jr, Podlaski FJ, Faherty DA, Familletti PC, Stern AS, Presky DH.

Ann N Y Acad Sci. 1996 Oct 31;795:1-12.

PMID:
8958912
21.

Genetically resistant mice lacking interleukin-12 are susceptible to infection with Leishmania major and mount a polarized Th2 cell response.

Mattner F, Magram J, Ferrante J, Launois P, Di Padova K, Behin R, Gately MK, Louis JA, Alber G.

Eur J Immunol. 1996 Jul;26(7):1553-9.

PMID:
8766560
22.

[The potential of interleukin-12 for use in cancer therapy].

Gately MK, Brunda MJ.

Gan To Kagaku Ryoho. 1996 Jul;23(8):961-71. Review. Japanese.

PMID:
8687231
23.

IL-12-deficient mice are defective in IFN gamma production and type 1 cytokine responses.

Magram J, Connaughton SE, Warrier RR, Carvajal DM, Wu CY, Ferrante J, Stewart C, Sarmiento U, Faherty DA, Gately MK.

Immunity. 1996 May;4(5):471-81.

24.

Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis.

Uyemura K, Demer LL, Castle SC, Jullien D, Berliner JA, Gately MK, Warrier RR, Pham N, Fogelman AM, Modlin RL.

J Clin Invest. 1996 May 1;97(9):2130-8.

25.

Biological function and distribution of human interleukin-12 receptor beta chain.

Wu CY, Warrier RR, Carvajal DM, Chua AO, Minetti LJ, Chizzonite R, Mongini PK, Stern AS, Gubler U, Presky DH, Gately MK.

Eur J Immunol. 1996 Feb;26(2):345-50.

PMID:
8617302
26.

Characterization of anti-mouse IL-12 monoclonal antibodies and measurement of mouse IL-12 by ELISA.

Wilkinson VL, Warrier RR, Truitt TP, Nunes P, Gately MK, Presky DH.

J Immunol Methods. 1996 Jan 16;189(1):15-24.

PMID:
8576576
27.

Interleukin-12: potential clinical applications in the treatment and prevention of infectious diseases.

Gately MK, Mulqueen MJ.

Drugs. 1996;52 Suppl 2:18-25; discussion 25-6. Review.

PMID:
8869832
28.

IL-12 protects immunocompetent and immunodeficient neonatal mice against infection with Cryptosporidium parvum.

Urban JF Jr, Fayer R, Chen SJ, Gause WC, Gately MK, Finkelman FD.

J Immunol. 1996 Jan 1;156(1):263-8.

PMID:
8598471
29.

High doses of interleukin-12 inhibit the development of joint disease in DBA/1 mice immunized with type II collagen in complete Freund's adjuvant.

Hess H, Gately MK, Rüde E, Schmitt E, Szeliga J, Germann T.

Eur J Immunol. 1996 Jan;26(1):187-91.

PMID:
8566065
30.

Administration of IL-12 during ongoing immune responses fails to permanently suppress and can even enhance the synthesis of antigen-specific IgE.

Germann T, Guckes S, Bongartz M, Dlugonska H, Schmitt E, Kolbe L, Kölsch E, Podlaski FJ, Gately MK, Rüde E.

Int Immunol. 1995 Oct;7(10):1649-57.

PMID:
8562510
31.

The IL-12 p40 homodimer as a specific antagonist of the IL-12 heterodimer.

Germann T, Rüde E, Mattner F, Gately MK.

Immunol Today. 1995 Oct;16(10):500-1. No abstract available.

PMID:
7576055
32.

IL12 receptors and receptor antagonists.

Presky DH, Gubler U, Chizzonite RA, Gately MK.

Res Immunol. 1995 Sep-Oct;146(7-8):439-45. Review. No abstract available.

PMID:
8839143
33.

The role of IL-12 in the induction of organ-specific autoimmune diseases.

Trembleau S, Germann T, Gately MK, Adorini L.

Immunol Today. 1995 Aug;16(8):383-6. Review.

PMID:
7546194
34.

Administration of interleukin 12 in combination with type II collagen induces severe arthritis in DBA/1 mice.

Germann T, Szeliga J, Hess H, Störkel S, Podlaski FJ, Gately MK, Schmitt E, Rüde E.

Proc Natl Acad Sci U S A. 1995 May 23;92(11):4823-7.

35.

Administration of recombinant interleukin-12 to mice suppresses hematopoiesis in the bone marrow but enhances hematopoiesis in the spleen.

Tare NS, Bowen S, Warrier RR, Carvajal DM, Benjamin WR, Riley JH, Anderson TD, Gately MK.

J Interferon Cytokine Res. 1995 Apr;15(4):377-83.

PMID:
7627813
36.

Structure-function analysis of the p35 subunit of mouse interleukin 12.

Zou JJ, Schoenhaut DS, Carvajal DM, Warrier RR, Presky DH, Gately MK, Gubler U.

J Biol Chem. 1995 Mar 17;270(11):5864-71.

37.

Interleukin-12 profoundly up-regulates the synthesis of antigen-specific complement-fixing IgG2a, IgG2b and IgG3 antibody subclasses in vivo.

Germann T, Bongartz M, Dlugonska H, Hess H, Schmitt E, Kolbe L, Kölsch E, Podlaski FJ, Gately MK, Rüde E.

Eur J Immunol. 1995 Mar;25(3):823-9.

PMID:
7705414
38.

Administration of systemic or local interleukin-2 enhances the anti-tumor effects of interleukin-12 gene therapy.

Pappo I, Tahara H, Robbins PD, Gately MK, Wolf SF, Barnea A, Lotze MT.

J Surg Res. 1995 Feb;58(2):218-26.

PMID:
7861776
39.

Interleukin 12 administration induces T helper type 1 cells and accelerates autoimmune diabetes in NOD mice.

Trembleau S, Penna G, Bosi E, Mortara A, Gately MK, Adorini L.

J Exp Med. 1995 Feb 1;181(2):817-21.

40.

Role of interferon-gamma in mediating the antitumor efficacy of interleukin-12.

Brunda MJ, Luistro L, Hendrzak JA, Fountoulakis M, Garotta G, Gately MK.

J Immunother Emphasis Tumor Immunol. 1995 Feb;17(2):71-7.

PMID:
7647958
41.

Interleukin-12: a pivotal regulator of cell-mediated immunity.

Gately MK, Brunda MJ.

Cancer Treat Res. 1995;80:341-66. Review. No abstract available.

PMID:
8821585
42.

Mouse interleukin-12 (IL-12) p40 homodimer: a potent IL-12 antagonist.

Gillessen S, Carvajal D, Ling P, Podlaski FJ, Stremlo DL, Familletti PC, Gubler U, Presky DH, Stern AS, Gately MK.

Eur J Immunol. 1995 Jan;25(1):200-6.

PMID:
7843232
43.

Interleukin-12: potential role in cancer therapy.

Brunda MJ, Gately MK.

Important Adv Oncol. 1995:3-18. Review.

PMID:
7672811
44.

Human IL-12 p40 homodimer binds to the IL-12 receptor but does not mediate biologic activity.

Ling P, Gately MK, Gubler U, Stern AS, Lin P, Hollfelder K, Su C, Pan YC, Hakimi J.

J Immunol. 1995 Jan 1;154(1):116-27.

PMID:
7527811
45.

In vitro maturation of neonatal human CD8 T lymphocytes into IL-4- and IL-5-producing cells.

Byun DG, Demeure CE, Yang LP, Shu U, Ishihara H, Vezzio N, Gately MK, Delespesse G.

J Immunol. 1994 Dec 1;153(11):4862-71.

PMID:
7963550
46.

Biologic effects of recombinant human interleukin-12 in squirrel monkeys (Sciureus saimiri).

Sarmiento UM, Riley JH, Knaack PA, Lipman JM, Becker JM, Gately MK, Chizzonite R, Anderson TD.

Lab Invest. 1994 Dec;71(6):862-73.

PMID:
7807968
47.
48.

IL-12 regulates T helper type 1 cytokine responses in human infectious disease.

Sieling PA, Wang XH, Gately MK, Oliveros JL, McHugh T, Barnes PF, Wolf SF, Golkar L, Yamamura M, Yogi Y, Uyemura K, Rea TH, Modlin RL.

J Immunol. 1994 Oct 15;153(8):3639-47. Erratum in: J Immunol 1994 Dec 1;153(11):5347.

PMID:
7930584
49.

Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production.

Nastala CL, Edington HD, McKinney TG, Tahara H, Nalesnik MA, Brunda MJ, Gately MK, Wolf SF, Schreiber RD, Storkus WJ, et al.

J Immunol. 1994 Aug 15;153(4):1697-706.

PMID:
7913943
50.

Expression cloning of a human IL-12 receptor component. A new member of the cytokine receptor superfamily with strong homology to gp130.

Chua AO, Chizzonite R, Desai BB, Truitt TP, Nunes P, Minetti LJ, Warrier RR, Presky DH, Levine JF, Gately MK, et al.

J Immunol. 1994 Jul 1;153(1):128-36.

PMID:
7911493

Supplemental Content

Loading ...
Support Center